Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
January 25, 2016 7:05 AM ESTFive Patents for PROCYSBI Now Listed in FDA Orange Book
Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old
NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that a U.S. PROCYSBI patent, number 9,233,077, is now listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent, entitled Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same, covers the enteric coated micro-bead formulation of PROCYSBI as well as... More
